

Application No.: 10/697,013

Docket No.: 21581-00285-US1

REMARKS

Claims 6-23 are now in the application. Claim 14 has been amended to recite "halogen" in place of "iodine" for purposes of clarification to render it consistent with claim 12 from which it depends. The amendment to claim 14 does limit its scope. Newly presented claim 18 is an independent claim along the lines of claims 6 and 12 except that it incorporates recitations from original claim 1. Claims 19-23 correspond to claims 13-17, respectively, except that they depend from claim 18 instead of claim 12. Accordingly, new presented claims 18-23 do not introduce any new matter. The indication that that claims 7, 9, 11, 13, 15, and 17 contain allowable subject matter is hereby noted.

The rejection of Claims 6, 8, 10, 12, 14, and 16 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 11 of U.S. Patent 6,693,142 has been overcome by the filing of the attached terminal disclaimer. The filing of the terminal disclaimer is not to be construed as an admission, estoppel or acquiescence. See *Quad Environmental Technology v. Union Sanitary District*, 20 USPQ2d 1392 (Fed. Cir. 1991) and *Ortho Pharmaceuticals Corp. v. Smith*, 22 USPQ2d 1119 (Fed. Cir. 1992).


In view of the above, consideration and allowance are, therefore, respectfully solicited.

In the event that the Examiner believes an interview might serve to advance the prosecution of this application in any way, the undersigned attorney is available at the telephone number noted below.

The Commissioner is hereby authorized to charge any fees or credit any overpayment associated with this communication including any extension fees to Deposit Account No. 22-0185.

Dated: 2-14-05

Respectfully submitted,

By 
Burton A. Amernick

Registration No.: 24,852
CONNOLLY BOVE LODGE & HUTZ LLP
1990 M Street, N.W., Suite 800
Washington, DC 20036-3425
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Applicant